These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 25910495)

  • 21. Association of indoxyl sulfate with fibroblast growth factor 23 in patients with advanced chronic kidney disease.
    Lin CJ; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Am J Med Sci; 2014 May; 347(5):370-6. PubMed ID: 24051956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism.
    Sakan H; Nakatani K; Asai O; Imura A; Tanaka T; Yoshimoto S; Iwamoto N; Kurumatani N; Iwano M; Nabeshima Y; Konishi N; Saito Y
    PLoS One; 2014; 9(1):e86301. PubMed ID: 24466013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of interactions between proteinuria, activity of fibroblast growth factor 23 and serum phosphate on renal progression in patients with chronic kidney disease: a result from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease study.
    Kim H; Park J; Nam KH; Jhee JH; Yun HR; Park JT; Han SH; Chung W; Oh KH; Park SK; Kim SW; Kang SW; Choi KH; Ahn C; Yoo TH
    Nephrol Dial Transplant; 2020 Mar; 35(3):438-446. PubMed ID: 30615179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
    Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P
    J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
    Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
    Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
    Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
    Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Grunwald JE; Pistilli M; Ying GS; Daniel E; Maguire M; Xie D; Roy J; Whittock-Martin R; Parker Ostroff C; Lo JC; Townsend RR; Gadegbeku CA; Lash JP; Fink JC; Rahman M; Feldman HI; Kusek JW;
    JAMA Ophthalmol; 2019 Jul; 137(7):767-774. PubMed ID: 31070679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.
    Mirza MA; Larsson A; Melhus H; Lind L; Larsson TE
    Atherosclerosis; 2009 Dec; 207(2):546-51. PubMed ID: 19524924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.
    Isakova T; Cai X; Lee J; Katz R; Cauley JA; Fried LF; Hoofnagle AN; Satterfield S; Harris TB; Shlipak MG; Sarnak MJ; Ix JH;
    J Bone Miner Res; 2016 Apr; 31(4):742-8. PubMed ID: 26590361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
    Sarmento-Dias M; Santos-Araújo C; Poínhos R; Oliveira B; Silva IS; Silva LS; Sousa MJ; Correia F; Pestana M
    Clin Nephrol; 2016 Mar; 85(3):135-41. PubMed ID: 26833300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA; Wolf M; Jüppner H; Messinger S; Kumar J; Wesseling-Perry K; Schwartz GJ; Furth SL; Warady BA; Salusky IB
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
    Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediation of the relationship between proteinuria and serum phosphate: Insight from the KNOW-CKD study.
    Jung JY; Ro H; Chang JH; Kim AJ; Lee HH; Han SH; Yoo TH; Lee KB; Kim YH; Kim SW; Park SK; Chae DW; Oh KH; Ahn C; Chung W
    PLoS One; 2020; 15(6):e0235077. PubMed ID: 32569271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGF23, Frailty, and Falls in SPRINT.
    Jovanovich A; Ginsberg C; You Z; Katz R; Ambrosius WT; Berlowitz D; Cheung AK; Cho M; Lee AK; Punzi H; Rehman S; Roumie C; Supiano MA; Wright CB; Shlipak M; Ix JH; Chonchol M
    J Am Geriatr Soc; 2021 Feb; 69(2):467-473. PubMed ID: 33289072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High fibroblast growth factor 23 is associated with coronary calcification in patients with high adiponectin: analysis from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD) study.
    Hyun YY; Kim H; Oh YK; Oh KH; Ahn C; Sung SA; Choi KH; Kim SW; Lee KB
    Nephrol Dial Transplant; 2019 Jan; 34(1):123-129. PubMed ID: 29701806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.